Current research indicates that in patients with type 2 diabetes, tirzepatide outperforms other GLP-1 receptor agonists, such as semaglutide, regarding glycosylated hemoglobin and weight control (Frías et al., 2021). Here, GLP1R is linked to type 2 diabetes mellitus.